Randomized trial of a multifaceted commercial weight loss program
Randomized trial of a multifaceted commercial weight loss program
复制标题
DOI：
10.1038/oby.2007.614
复制
发表时间：
2007-04-01
期刊：
影响因子：
6.9
通讯作者：
Quintana, Elizabeth L.
中科院分区：
文献类型：
--
作者：
Rock, Cheryl L.;Pakiz, Bilge;Quintana, Elizabeth L.
目的：测试商业减肥计划是否能促进超重或肥胖妇女的体重减轻，并描述其对血浆脂质、类胡萝卜素、激素和健康的影响。研究方法和程序：超重或肥胖妇女被随机分配到商业减肥计划或对照条件（n = 35）。结果：随机化。参与者年龄为41.1（11.4）岁（平均[标准差]），BMI为34.0 (3.5)kg/m(2)，体重为92.0 (11.1)kg。6个月时，通过意向治疗（ITT）分析，干预组的体重变化为-7.2 (6.7)kg和-7.8%(7.2%)，对照组为-0.3 (3.9)kg和-0.3% (4.5%)（n = 35, p < 0.01）。为期一年的ITT分析显示，干预组的体重、体重百分比、BMI、腰围和臀围的变化幅度明显大于对照组。干预组完成治疗1年后的体重变化为-7.3 (10.4)kg (n = 32)，对照组为-0.7 (5.6)kg (n = 33) (p < 0.01)，干预组为-7.8%(11.1%)，对照组为-0.7% (6.2%)（p < 0.01）。干预组高密度脂蛋白（HDL）胆固醇浓度明显升高。干预组空腹血清胰岛素在6个月时下降，对照组升高（p < 0.01）， 1年后差异无统计学意义（p = 0.05）。讨论：商业方案成功地促进了体重的减轻，并在1年内显著保持，并促进了血脂和激素浓度的有利变化。
Objective: To test whether a commercial weight loss program promotes greater weight loss in overweight or obese women compared with control conditions and to describe the effect on plasma lipids, carotenoids, hormones, and fitness.Research Methods and Procedures: Overweight or obese women were randomized to commercial weight loss program or control conditions (n = 35 each).Results: At randomization. participants were 41.1 (11.4) (mean [standard deviation]) years, BMI 34.0 (3.5) kg/m(2), and weight 92.0 (11.1) kg. At 6 months, change in weight by intent-to-treat (ITT) analysis was -7.2 (6.7) kg and -7.8% (7.2%) in the intervention group vs. -0.3 (3.9) kg and -0.3% (4.5%) in the control group (n = 35 for each; p < 0.01). One-year ITT analysis revealed significantly greater chan-e in weight, percent weight, BMI, and waist and hip circumferences in the intervention vs. control group. Completers at 1 year exhibited change in weight of -7.3 (10.4) kg for the intervention group (n = 32) vs. -0.7 (5.6) kg for controls (n = 33) (p < 0.01), and -7.8% (11.1%) weight change for the intervention group vs. -0.7% (6.2%) for controls (p < 0.01). High-density lipoprotein (HDL) cholesterol concentration increased significantly in the intervention group. Fasting serum insulin decreased in the intervention but increased in the control group at 6 months (p < 0.01), remaining different at 1 year (p = 0.05).Discussion: The commercial program successfully facilitated weight loss, which was notably maintained at 1 year, and promoted favorable changes in plasma lipid and hormone concentrations.